Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04816721 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate EDP 938 Regimens in Children With RSV
A Phase 2 study of Respiratory Syncytial Virus (RSV), sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
- 20
- Study locations
NCT04816721 is a Phase 2 study of Respiratory Syncytial Virus (RSV) that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 99 participants, below the 6,747-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04816721, a Phase 2 study of Respiratory Syncytial Virus (RSV), has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EDP-938
Study Locations (20)
California
- Memorial Care Miller Children's and Women's Hospital - Long Beach
- University of California Los Angeles (UCLA) - Los Angeles
- University of California Davis - Sacramento
Louisiana
- MedPharmics - Lafayette - Lafayette
- LSU Health - Shreveport
- Willis-Knighton Health System - Shreveport
Other
- Hospital Interzonal Dr Jose Penna - Bahía Blanca
- Clínica Privada del Sol - Buenos Aires
- Instituto Medico Rio Cuarto - Río Cuarto
Florida
- Nemours Children's Hospital - Orlando
- South Tampa Center for Advanced Healthcare - Tampa
Texas
- Driscoll Children's Hospital - Corpus Christi
- Children's Health Specialty Center Dallas Campus - Dallas
Idaho
- Rexburg Pediatrics - Rexburg
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Kentucky
- Norton Children's Research Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2024-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04816721
The ClinicalTrials.gov registry entry for NCT04816721 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,747-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (99% lower). The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus (RSV) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04816721 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Louisiana, Other.
Frequently Asked Questions
What is clinical trial NCT04816721 about?
NCT04816721 is a clinical study titled "A Study to Evaluate EDP 938 Regimens in Children With RSV". A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
What is the current status of trial NCT04816721?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2022-04-26. Estimated completion is 2024-08-19.
What conditions does trial NCT04816721 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus (RSV).
What interventions are being tested in trial NCT04816721?
The interventions under investigation include: Placebo (DRUG), EDP-938 (DRUG).
Who is sponsoring clinical trial NCT04816721?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04816721 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus (RSV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
RECRUITING · Phase 2
-
RSV Vaccine Pregnancy Registry
RECRUITING
-
Systems Biological Analysis of Immune Responses to RSV Vaccine
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
ACTIVE NOT RECRUITING · Phase 1
-
Transplacental Transmission of RSV (TTRSV)
ACTIVE NOT RECRUITING
-
Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.